Avant Immunotherapeutics Report issue

For profit Phase 2
Founded: Phillipsburg NJ United States (1983)
Status: Acquired by Celldex Therapeutics (2008)

Organization Overview

First Clinical Trial
2004
NCT00082121
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (5)

Key: Avant Immunotherapeutics (3) Acquired (2)

autologous engineered skin substitute (1 trial)

eltoprazine (2 trials)

peru-15-pctb (1 trial)

tp10 (1 trial)

ty800 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aortic Valve Insufficiency (Phase 2)

Arteriosclerosis (Phase 2)

Cholera (Phase 2)

Coronary Artery Disease (Phase 2)

Diarrhea (Phase 2)

Fever (Phase 2)

Ischemia (Phase 2)

Mitral Valve Insufficiency (Phase 2)

Myocardial Ischemia (Phase 2)

Typhoid Fever (Phase 2)

Vibrio Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 5